Abstract
In this study based on real-world data of Asian patients in primary care, it was shown that although statin titration substantially affected LDL-C levels and LDL-C goal attainment rates, the magnitude was lower than results reported from clinical trials. These results should be taken into consideration and provide further insight to clinicians when making statin adjustment recommendations in order to achieve LDL-C targets in clinical practice, particularly for Asian populations.
Introduction: The Real-World Effectiveness Gap
Statins are the gold standard for lowering LDL-cholesterol (LDL-C) and reducing cardiovascular risk. While clinical trials suggest that initiating or doubling a statin dose can reduce LDL-C by 30% to over 60%, these trials often utilize highly selected populations and strict protocols. In the "messy" reality of primary care—especially among Asian populations who may have different genetic responses and cultural attitudes toward long-term medication—the actual results are often lower. This study quantifies the magnitude of LDL-C change and the rate of "goal attainment" when clinicians adjust statin dosages in a real-world Asian primary care setting.
Methodology and Data Sources
The researchers conducted a retrospective cohort study using five years of Electronic Medical Record (EMR) data (2014–2019) from the SingHealth Polyclinics system in Singapore. The study population included 11,499 multi-ethnic Asian adults diagnosed with dyslipidaemia.
Statins were classified into Low (LI), Moderate (MI), and High-intensity (HI) based on 2018 ACC/AHA guidelines. The researchers identified "titration events"—changes in statin intensity—and compared "pre-LDL" levels (within 1 year before the change) to "post-LDL" levels (between 6 weeks and 1 year after the change). The 6-week buffer ensures the drug has reached steady-state efficacy.
Patients were assigned to four cardiovascular risk groups (Low to Very High) using a modified Framingham risk calculator to determine their specific LDL-C targets. The final analytical sample consisted of 1,962 pairs of LDL-C values specifically associated with a statin titration event.
Key Findings and Results
The most striking insight is the "effectiveness gap": real-world LDL-C reduction (21.6% to 28.9%) is roughly half of what is seen in clinical trials.
The High-Intensity Paradox
Interestingly, initiating a High-Intensity (HI) statin resulted in less LDL-C reduction (25.2%) than initiating a Moderate-Intensity (MI) statin (28.9%). The authors hypothesize this is due to lower adherence; patients may fear side effects from higher doses and skip pills more frequently. This suggests that simply increasing dose intensity does not guarantee better outcomes if patient behavior is not addressed.
Goal Attainment and De-escalation
Up-titration significantly boosted the chances of hitting cholesterol targets. For example, initiating a HI statin in a previously untreated patient increased the odds of hitting the target by 23.3 times (OR 23.3). After up-titration, the percentage of patients meeting their LDL-C goals improved by 26.5% to 47.1%. Conversely, down-titration or discontinuation led to significant LDL-C rebounds (up to 32.1% increase), highlighting the risk of reducing therapy even when a patient seems stable.
Discussion and Limitations
The paper notes that Asians often exhibit higher plasma concentrations of certain statins (like Rosuvastatin) compared to Caucasians. While this might suggest they need lower doses, the real-world data shows that suboptimal adherence still prevents many from reaching their targets.
Limitations include the single-center nature of the study and the use of prescription records as a proxy for adherence. As a retrospective study, it cannot account for changes in diet or exercise. The authors suggest developing clinical decision support tools based on this real-world data to help doctors set more realistic expectations and better manage statin adjustments in Asian patients.
Summary updated